Venetoclax and Azacitidine Treatment in Relapsed Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation: A Cohort Study in the Real-World Setting of a Tertiary Center

• DOI: 10.4274/tjh.galenos.2023.2023.0089
• Publication Date: 2023-09-01T13:39:27Z
• Authors: Hakan Göker; Olgu Erkin Çınar; Haluk Demiroğlu; Ümit Yavuz Malkan; Elifcan Aladağ Ka...; Yahya Büyükaşık
• Keywords: Azacitidine; Venetoclax

To the Editor,Approximately half of all acute myeloid leukemia (AML) patients eventually relapse after allogeneic stem cell transplantation (aHSCT) [1], and best treatment aHSCT is unclear.The present study sought to demonstrate outcomes combination venetoclax azacitidine (VEN-AZA) in with relapsed AML who were unsuitable for intensive regimens.This had a single-center, retrospective cohort design.The sample consisted treated at Hacettepe University Türkiye.Ethical approval was obtained from local ethics committee document number GO22/307.Adult aged >18 years admitted between January 2018 December 2021 screened.The inclusion criteria receiving AML, experiencing aHSCT, being VEN-AZA combination.Patients promyelocytic excluded.The basic demographic data patients, test results, treatments received, disease status, final causes death recorded.